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Abstract 
Cancer cells reprogram their metabolism to meet increased biosynthetic demands, commensurate 
with elevated rates of replication. Pyruvate kinase M2 (PKM2) catalyzes the final and rate-limiting 
step in tumor glycolysis, controlling the balance between energy production and the synthesis of 
metabolic precursors. We report here the synthesis and evaluation of a positron emission 
tomography (PET) radiotracer, [11C]DASA-23, that provides a direct non-invasive measure of 
PKM2 expression in preclinical models of glioblastoma multiforme (GBM). In vivo, orthotopic 
U87 and GBM39 patient-derived tumors were clearly delineated from the surrounding normal 
brain tissue by PET imaging, corresponding to exclusive tumor-associated PKM2 expression. In 
addition, systemic treatment of mice with the PKM2 activator, TEPP-46, resulted in complete 
abrogation of the PET signal in intracranial GBM39 tumors. Together, these data provide the basis 
for the clinical evaluation of imaging agents that target this important gatekeeper of tumor 
glycolysis.  
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Introduction 
Tumors undergo metabolic reprogramming to support the synthesis of new macromolecules 
required for rapid cell division, which also provides a selective advantage for progression and 
protection from cell death (1). The concept of metabolic adaptation in tumors was first described 
by Otto Warburg in the 1920s after the discovery that cancer cells display increased rates of 
glucose utilization in comparison to normal tissue, even under aerobic conditions (2). We now 
know that the metabolic transformation of cancer cells encompasses multiple interconnecting 
metabolic networks (3, 4), with feedback loops and crosstalk acting to provide plasticity and help 
the cells survive the steep and localized nutrient and oxygen gradients present in the harsh tumor 
microenvironment (5). 
 
Central to tumor metabolism is the glycolytic pathway, which sustains tumors through the 
generation of ATP and synthesis of intermediates for biosynthetic reactions. Pyruvate kinase (PK) 
catalyzes the final and rate-limiting reaction in glycolysis, converting phosphoenolpyruvate (PEP) 
to pyruvate by transferring the high-energy phosphate group to ADP to produce ATP. PK consists 
of four isoforms, of which the spliced variant, PKM2, is preferentially expressed in all cancers 
studied to-date, regardless of their tissue of origin (6). PKM2 is allosterically regulated by the 
stabilization of a highly active tetramer relative to monomeric/dimeric PKM2. The tetramer of 
PKM2 has a high affinity for PEP, favoring synthesis of ATP and pyruvate, whereas the 
monomer/dimer has reduced activity because of its low affinity for PEP at physiological 
concentrations (7). When PKM2 is in the monomeric/dimeric conformation, reduced glycolytic 
flux through to pyruvate results in the accumulation of precursors for the biosynthesis of amino 
acids, nucleic acids, and phospholipids, commensurate with the production of reducing power 
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through pentose phosphate pathway-derived NADPH (8). A dynamic equilibrium between the two 
states of PKM2 enables tumor cells to switch between anabolic and catabolic metabolism (Fig. 1). 
Alternative splicing of PKM2 is controlled by c-Myc and HIF-1 oncogenes (reviewed in (9)), with 
quaternary structure of PKM2 tightly regulated by the glycolytic intermediate fructose 1,6-
bisphosphate (FBP) (10) and growth factor signaling (11). In recent years, PKM2 has been targeted 
for cancer therapy through the development of small molecule activators that promote tetramer 
formation (12, 13).  
 
Given the importance of PKM2 in the regulation of tumor metabolism, we sought to noninvasively 
measure its expression through the development of a PKM2-specifc radiopharmaceutical. A class 
of N,N-diarylsulfonamides (DASA) was reported by Boxer et al. in 2010 as highly promising 
PKM2 activators (12), known to promote PKM2 tetramer formation through binding at the subunit 
interaction interface of the PKM2 dimer in an allosteric pocket distinct from the binding site of 
fructose 1,6-bisphosphate and to inhibit tumor growth in vivo (14). Here we report the synthesis 
and evaluation of a positron emission tomography (PET) radiotracer for dimeric PKM2, 
[11C]DASA-23, based on this class of compounds (Fig. 2A). DASA-23 was selected as a suitable 
candidate for 11C labeling because of its high potency as a PKM2 activator (maximum activating 
concentration, AC50 = 90 nM (12)), favorable selectivity for PKM2 compared to other pyruvate 
kinase isozymes (PKM1, PKR, and PKL (12)) through reversible binding, and the presence of a 
methoxy moiety, which allows 11C radiolabeling without modifying its structure. This chemotype 
is known to activate the PKM2 isoform by decreasing the Km for PEP whilst maintaining PKM2’s 
affinity for ADP; akin to the action of FBP (12). We demonstrate the ability of [11C]DASA-23 to 
detect tumor-specific PKM2 in subcutaneous and orthotopic mouse models of human glioma in 
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vivo. Finally, we confirm the in vivo specificity and selectivity of [11C]DASA-23 for PKM2 
through pharmacological challenge in mice bearing patient-derived orthotopic xenografts (PDX) 
treated with TEPP-46, a structurally distinct class of PKM2 activator. 
  
 
Results 
[11C]DASA-23 is rapidly taken up by tumor cells.  
PKM2-23 was labeled at its aromatic methoxy moiety with 11C (t1/2 = 20.4 min) from the 
corresponding nor-derivative of DASA-23 and the highly efficient methylation reagent 
[11C]CH3OTf (Fig. 2A), with a radiochemical yield of 2.4 ± 0.8%, >99% radiochemical purity, 
and a specific activity of 159.2 ± 94.3 GBq/µmol at the end of synthesis (EOS; n = 12). The identity 
of the radiochemistry precursor and cold standard was confirmed through mass spectrometry and 
nuclear magnetic resonance (NMR) spectroscopy, and the identity of the radiotracer ([11C]DASA-
23) was confirmed by high performance liquid chromatography (HPLC) via co-injection with cold 
standard (fig. S1, S2, and S3, respectively). In cell studies, addition of [11C]DASA-23 resulted in 
rapid and extensive cellular uptake in both HeLa and U87 tumor cells, reaching 14.9 ± 2.0 % 
radioactivity/mg protein and 19.6 ± 2.0 % radioactivity/mg protein, respectively, by 30 min (Fig. 
2B & C). Removal of exogenous radioactivity resulted in efflux of cell-associated activity, with 
~40% of the initial intracellular radioactivity retained 30 min after removal of exogenous 
[11C]DASA-23 for both cell lines (Fig. 2B & C). 
 
Retention of [11C]DASA-23 is closely correlated to PKM2 expression 
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To determine the specificity of [11C]DASA-23 in cancer cells, we modulated PKM2 protein 
expression in culture through small inhibitory RNA (siRNA). HeLa cells were selected due to their 
relative ease of transfection. Knockdown of PKM2 was observed at 48 hours after addition of 
PKM2 siRNA (siPKM2), with nearly complete protein ablation detected by 72 hours (Fig. 3A). 
Extended incubation of cells in culture medium in the presence of scrambled, non-targeting siRNA 
(siCtrl) induced a temporal increase in PKM2 protein expression. Low levels of PKM1 were 
measured in naïve cells and 72 hours after transfection with either siPKM2 or siCtrl (Supplemental 
Fig. S4). Next, we compared cell uptake of [11C]DASA-23 to protein concentrations of PKM2 
after siRNA knockdown. A significant 16.5% reduction in [11C]DASA-23 uptake was measured 
in siPKM2 cells versus those transfected with control siRNA just 24 hours after transfection (P = 
0.011; n = 3). After 72 hours, [11C]DASA-23 uptake in siPKM2 cells was reduced to 44.5% of 
siCtrl cells (P < 0.001; n = 3; Fig. 3B). [11C]DASA-23 strongly correlated with PKM2 protein 
expression, determined from analysis of the same cell lysates (R2 = 0.83; P = 0.005), albeit with 
some non-specific cell retention in cells with low PKM2 expression (Fig. 3C). 
 
 [11C]DASA-23 shows favorable characteristics for in vivo tumor imaging 
Given the favorable tumor cell retention and specificity of [11C]DASA in culture, we established 
small animal [11C]DASA-23-PET in a nude mouse model implanted with subcutaneous (s.c.) U87 
human glioma xenografts. [11C]DASA-23 radiotracer distribution was characterized by liver 
uptake and clearance through both renal and hepatobiliary routes, accompanied by good tumor 
accumulation (Fig. 4A). Ex vivo biodistribution studies corroborated the PET imaging data (Fig. 
4B). Of note, low [11C]DASA-23 radioactivity was present in the brain 60 min after injection, at 
0.86 ± 0.09 % of the injected dose (ID)/g. At this time point, U87 tumor uptake was 1.78 ± 0.23 
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%ID/g (n = 4 animals), and the tumor-to-blood, -muscle, and -brain ratios were 1.1, 1.6, and 2.1, 
respectively. Additionally, [11C]DASA-23 showed excellent stability in plasma ex vivo, with >96% 
of the parent compound remaining after 60 min (Fig. 4C).  
 
Dynamic [11C]DASA-23 PET imaging confirmed rapid liver and kidney uptake, followed by 
clearance through the bladder and small intestine (Fig. 4D & E). Rapid tumor uptake of 
[11C]DASA-23, peaking at 10 minutes, preceded a slow washout of radioactivity over the 
remaining 50 minutes (Fig. 4F). Muscle uptake of [11C]DASA-23 followed a similar pattern of 
retention but at lower levels. This was contrasted with [11C]DASA-23 uptake in the brain, where 
high initial delivery, peaking 30 s after injection (13.4 ± 1.9 %ID/g), was followed by rapid 
clearance, reaching low steady-state levels (2.3 ± 0.2 %ID/g) by 10 min after injection.    
 
[11C]DASA-23 accumulates in orthotopically-growing U87 tumors 
We next explored the ability of [11C]DASA-23 to image orthotopically grown U87 tumors. 
MicroPET after i.v. injection of [11C]DASA-23 clearly allowed the detection of intracerebral 
tumors, shown in the fused PET-CT images (Fig. 5A; the corresponding 3D movie is displayed as 
movie S1, with a non-tumor-bearing mouse shown in movie S2 for comparison). Similarly to s.c. 
xenograft tumors, U87 tumor kinetics were characterized by rapid initial uptake preceding slow 
washout. In comparison, radioactivity from the control, contralateral, region of the brain reached 
similar levels of radiotracer delivery (P > 0.05; fig. S5), but it was not retained (Fig. 5B). Time 
course images of initial [11C]DASA-23 uptake in the healthy brain and subsequent retention in 
orthotopic U87 tumors are shown in fig. S6. By 30 min after injection, [11C]DASA-23 radioactivity 
in the tumor was 1.68 ± 0.47 %ID/g versus 0.78 ± 0.18 %ID/g in the contralateral background 
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tissue (n = 6; P = 0.003). To confirm that the PET signal corresponded with orthotopically-growing 
tumors, we performed contrast-enhanced MRI on the same animals (Fig. 5C) and co-registered 
these with the [11C]DASA-23-PET images (Fig. 5D). Contrast-enhancing U87 tumors, clearly 
defined in the T1-weighted images, excellently matched the corresponding microPET images. It is 
important to note that the trace amount of [11C]DASA-23 (~200 pmol) used here was ~15,000 
lower than the amount used in previous drug studies (~3 µmol) (14). 
 
After imaging, the brains of tumor-bearing mice were excised for analysis by histopathology. H&E 
staining confirmed excellent correlation of PET signal intensity with histopathological findings 
(Fig 5E). The PET signal of orthotopic U87 tumors was sharply delineated from the surrounding 
brain tissue (Fig. 5D), matching the pattern of cytosolic PKM2 expression shown in tissue sections 
(Fig. 5E and fig. S7). PKM1 expression was exclusively located in the normal healthy brain and 
absent from intracranial tumors (Fig. 5E). At higher magnifications (10; Fig. 5E insert), U87 
tumor cells infiltrating away from the margins of the primary tumor were clearly delineated 
through the presence of PKM2 and absence of PKM1. Localization of [11C]DASA-23 to small (~1 
mm diameter) intracranial PKM2-positive tumors was shown through ex vivo autoradiography 
(fig. S8). Together, these data highlight the ability for [11C]DASA-23-PET to clearly detect 
orthotopically growing human gliomas through measurement of tumor-specific PKM2 expression. 
 
[11C]DASA-23 shows utility as a PKM2 companion diagnostic in patient-derived intracranial 
tumors 
Patient-derived xenograft (PDX) models are enhanced preclinical tools that better represent human 
tumor biology and patient response to therapy (15). To test whether [11C]DASA-23-PET could 
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image these more clinically relevant tumors, we implanted GBM39 PDXs orthotopically in the 
brains of nude mice and monitored their growth via bioluminescence imaging (BLI). By 50 days 
after implantation, a strong BLI signal originating from the head of GBM39 tumor-bearing mice 
was evident (Fig. 6A). Mice were subsequently imaged with [11C]DASA-23, which clearly 
identified the intracerebral tumors (Fig. 6B), appearing as distinct regions of infiltrative growth 
(Fig. 6C and movie S3).  
 
Having previously demonstrated the specificity of [11C]DASA-23 for  the detection of PKM2 in 
cell culture (Fig. 3), we determined whether the PET signal originating from the intracranial 
tumors in vivo corresponded to tumor-specific PKM2 expression. The short half-life of carbon-11 
permitted the use of the same mice in longitudinal studies, where [11C]DASA-23 tumor uptake 
was assessed at baseline and subsequently after challenge with a blocking agent, 24 hours after 
initial evaluation. A structurally distinct PKM2 activator, TEPP-46, a highly selective PKM2 
activator which binds with nM affinity (16), was selected to test the specificity of [11C]DASA-23 
for PKM2. One hour after TEPP-46 injection, animals were reimaged with [11C]DASA-23, which 
revealed complete ablation of tumor signal to background levels present in the healthy contralateral 
regions of the brain (Fig. 6B & C and movie S4). This was expected because DASA-23 and TEPP-
46 share the same PKM2 binding pocket, with TEPP-46-bound PKM2 made inaccessible for 
[11C]DASA-23 binding and retention in tissues. Of interest was the reduction of retention of 
[11C]DASA-23 in the harderian glands (Fig. 6C and movie S4), likely indicating PKM2 expression 
in this tissue. Contrast-enhanced MRI performed at the end of the study confirmed the presence of 
enhancing infiltrative tumors (Fig. 6D), with tumor-associated [11C]DASA-23 retention 30 min 
after radiotracer injection reduced from 1.61  0.25 % ID/g at baseline to 0.93  0.10 % ID/g after 
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TEPP-46, a 42% decrease (P = 0.0009; n = 7; Fig. 6E). The uptake in control, contralateral healthy 
brain was 0.79  0.18 % ID/g (P = 0.10).  As with U87 tumors, autoradiography of excised 
GBM39-containing brains revealed precise localization of radioactivity to small PKM2-expressing 
tumors (figure 8D-F). 
 
 
Discussion 
Tumor cells reprogram their metabolism in response to the increased anabolic and catabolic 
demands of highly proliferative cells. For many metabolic pathways, the balance between 
biomolecular synthesis and energy production is highly regulated. An elegant example is the case 
of acetyl CoA carboxylase, which controls the opposing rates of fatty acid synthesis and β-
oxidation on the basis of intracellular concentrations of acetyl CoA and malonyl CoA (17). Altered 
tumor glycolysis is mediated, in part, by PKM2 through transcriptional and epigenetic means (18-
20), with a growing body of evidence demonstrating a critical role of PKM2 in tumorigenesis and 
progression (6). Further evidence suggests that PKM2 might provide a similar regulatory switch 
to acetyl CoA carboxylase: controlling the balance between glycolytically-derived anabolic and 
catabolic metabolism (8, 11, 21, 22). PKM2 has also been shown to translocate to the nucleus, 
where it functions to promote cell proliferation through interaction with HIF, STAT 3, Oct 4, and 
β-catenin (reviewed in (9)). 
 
Clinically relevant imaging agents and modalities for the direct, non-invasive imaging of PKM2 
are a topic of great interest and importance. PKM2 is overexpressed in tumors (6) and expressed 
in most tissues to varying degrees, with the exception of adult muscle, brain, and liver (23-25). 
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Given the intrinsically low background of PKM2 in the brain, we asked whether PKM2 is 
upregulated in transformed human glioblastoma cells, evaluated in orthotopic mouse models of 
the disease, and whether we could measure this transformation noninvasively through imaging. 
We developed a PET radiotracer for PKM2 by labeling a PKM2 activator, DASA-23, with carbon-
11. DASA-23 has been shown to display selective activation of PKM2 (AC50 = 90 nM) versus 
other pyruvate kinase isozymes, PKM1, PKR, and PKL (12). Carbon-11 was selected for 
radiolabelling DASA-23 to retain its structure and therefore PKM2-binding selectivity.  
 
In the present study, high [11C]DASA-23 tumor cell uptake was measured in culture, with uptake 
strongly correlated to PKM2 protein expression. Nevertheless, we observed modest non-specific 
binding of [11C]DASA-23 to cells with low PKM2 expression, which could reduce tumor-to-
background contrast in living subjects. Because DASA-based activators are known to reversibly 
bind to dimeric PKM2 (14), efflux of the radiotracer from tumor cells after removal of exogenous 
activity was expected, although this occurred at a relatively slow rate. Of note was the ability of 
[11C]DASA-23 to measure increased PKM2 expression in cells after prolonged incubation without 
the replacement of fresh medium (up to 72 hours). Cell adaptation to a reduced nutrient 
environment, akin to poorly perfused tumors in vivo, hints at an important role for PKM2 in the 
maintenance of metabolic homeostasis. When glucose is abundant, PKM2 is degraded via 
acetylation and chaperone-mediated autophagy, a process which is inhibited under nutrient stress 
(20). The ability to detect chronically nutrient-deprived cells through PKM2 imaging, may provide 
insights into tumor progression and metastasis, given that these cells are relatively chemoresistant 
(5). 
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Given the promising in vitro uptake profile and relatively high lipophilicity (cLogP = 3.4, 
ChemDraw Bio 13.0) of [11C]DASA-23, required for diffusion across the blood brain barrier, we 
explored [11C]DASA-23 for the preclinical in vivo imaging of human glioma. [11C]DASA-23 could 
clearly image s.c. U87 tumor xenografts. The combined renal and hepatobiliary excretion profile 
for [11C]DASA-23, however, may limit the imaging of PKM2 to tumors of the brain and upper 
thoracic region. Tumor-to-muscle and blood background ratios, although statistically significant, 
were below those typically observed with FDG-PET (26), which may further limit the assessment 
of PKM2 status to tumors of the brain and other tissues.  We obtained PET/MR images of 
orthotopically-grown U87 gliomas, with [11C]DASA-23 retention limited to tumor tissue. Low 
background radioactivity was detected in the brain after rapid initial uptake and washout, as 
predicted by the absence of PKM2 expression in this tissue (25), which was confirmed by our 
immunohistochemistry results. Indeed, PKM2 expression was exclusively confined to the 
intracranial tumor, which lacked PKM1. Autoradiographic analysis of tumor sections after saline 
perfusion, which removed un-bound/intravascular radioactivity from the brain, further confirmed 
tumor-specific binding of [11C]DASA-23. 
 
The increased glucose utilization of tumors in comparison to normal tissue (the “Warburg effect”) 
has previously been exploited clinically to detect tumors and their response to treatment by [18F]2-
fluoro-2-deoxy-D-glucose ([18F]FDG) PET. 18F-FDG-PET is approved for use for the diagnosis of 
the majority of cancers (27), with particular utility for detecting metastases and nodal disease that 
appear normal on x-ray computed tomography scans (28). However, a high background uptake by 
surrounding normal tissue can mask tumor uptake, for example, in the brain (29). Thus, 
[11C]DASA-23 has the potential to play an important role in the noninvasive measurement of 
12 
malignancies where FDG fails. Several other radiotracers, such as 3,4-dihydroxy-6-[18F]fluoro-
phenylalanine ([18]F-FDOPA) (30), O-(2-[18F]fluoroethyl)-L-tyrosine (FET) (31), 4-[18F]-(2S,4R)-
fluoroglutamine (32), and (4S)-4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) (33), have shown 
great value for imaging tumors of the brain. The primary aim of our study, however, was to non-
invasively measure PKM2 status in these tumors. Given the great interest in targeting PKM2 for 
cancer therapy (12, 14, 34, 35), we additionally explored the ability of [11C]DASA-23 to report on 
the binding efficacy of these agents using orthotopically implanted PDX models of GBM. In these 
longitudinal studies, infiltrative GBM39 tumors were clearly delineated by PET, with tumor-
specific retention of [11C]DASA-23 abolished after pretreatment of the same animals with a bolus 
of TEPP-46, a structurally distinct class of PKM2 activators known to bind the same allosteric site 
as the DASA-class of activators (14). These data provide further evidence of the in vivo specificity 
of [11C]DASA-23 for reporting on tumor-specific PKM2 expression and a potential role for both 
drug screening and the evaluation of precision medicine strategies. Furthermore, the observation 
that temozolomide-treated glioblastomas have reduced PKM2 expression (36) indicates that 
[11C]DASA-23 may also provide a means to measure the efficacy of more traditional therapeutics. 
 
In conclusion, we have synthesized and evaluated an imaging agent for the measurement of 
dimeric PKM2, [11C]DASA-23. Through this work we showed that [11C]DASA-23 enables the 
preclinical detection of orthotopically-growing human glioblastoma with aberrantly expressed 
PKM2. This study sets the foundation for the clinical translation of [11C]DASA-23 for the imaging 
of primary brain tumors and potentially also other tumors that metastasize to the brain. In addition, 
our study confirms that [11C]DASA-23 PET may be useful as a companion diagnostic to aid the 
development of the next generation of PKM2 activators.  
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Materials and methods 
Study Design 
The primary research objective was to design and synthesize an imaging agent to noninvasively 
measure tumor-specific pyruvate-kinase M2 (PKM2) in living subjects via PET. 6-7 animals per 
group were used for the evaluation of PKM2 in orthotopic models of GBM, calculated with 90% 
power and a 5% significance level. For TEPP-46 treatment studies, animals were randomized 
before imaging and subsequent treatment. All outliers were included in the analysis and no data 
were excluded. Authors were not blinded to the results. A minimum of 3 experimental replicates 
were recorded for all in vitro data. 
 
Cell culture 
HeLa cells (ATCC) and U87 human glioma cells (ATCC) were grown in Dulbecco modified Eagle 
medium (DMEM; Life Technologies), containing 10% FBS, 2 mM L-glutamine and 2.5 mL 
penicillin/streptomycin (100 IU.mL-1/100 mg.mL-1). GBM39, transfected with a lentiviral vector 
that expressed a fusion protein of GFP and firefly luciferase, was received as a gift from Dr. Paul 
Mischel (Ludwig Institute for Cancer Research, University of California, San Diego). GBM39 
cells were grown in a defined, serum-free medium consisting of a 1:1 mixture of Neurobasal-A 
Medium DMEM/F12 that also contained HEPES Buffer Solution (10 mM), MEM sodium 
pyruvate solution (1 mM), MEM non-essential amino acids solution 10 mM (1), GlutaMAX-I 
Supplement (1), and antibiotic-antimycotic (1) from Life Technologies Inc. The full working 
medium was additionally supplemented with H-EGF (20 ng/mL), H-FGF-basic-154 (20 ng/mL), 
H-PDGF-AA (10 ng/mL), H-PDGF-BB (10 ng/mL), and heparin solution, 0.2% (2 µg/mL) as 
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growth factors (all from Shenandoah Inc.) and B-27 (Life Technologies Inc). All cells were 
propagated at 37°C in a humidified atmosphere containing 5% CO2.  
 
Precursor and cold standard synthesis 
The precursor for radiosynthesis was obtained through the reaction scheme illustrated in Figure 
2A. 1-tert-butyloxycarbonyl(BOC)-piperazine 1 (1.34 mmol, 1 equiv.) was dissolved in 
dichloromethane (2.5 mL) under nitrogen and cooled to 0 °C. Triethylamine (2.68 mmol, 2.0 
equiv.) was added followed by portion-wise addition of 2,6-difluorobenzenesulfonyl chloride 2 
(1.48 mmol, 1.1 equiv.). The reaction was stirred at 0 °C for one hour and quenched with saturated 
aqueous ammonium chloride solution. The organic layer was washed with brine, dried over sodium 
sulfate, and concentrated in vacuo. The residue was purified via silica gel chromatography using 
a 95/5-5/95, hexane/EtOAc (v/v) gradient to give tert-butyl 4-((2,6 difluoro-phenyl)-
sulfonyl)piperazine-1-carboxylate 3 as white crystals (80% yield).  
 
BOC protected compound 3 (1.04 mmol) was dissolved in dichloromethane (1 mL) and cooled to 
0°C. Trifluoroacetic acid (TFA, 1 mL) was added, and the reaction was monitored by TLC. After 
the reaction was complete, the solvents were evaporated in vacuo to yield the TFA salt of 
compound 4 as a light yellow oil, which was carried onto the next step without further purification. 
The oily residue 4 was dissolved in dichloromethane (2 mL) and cooled to 0°C. Triethylamine 
(4.16 mmol, 4 equiv.) was added followed by portion-wise addition of 4-hydroxybenzene-1-
sulfonyl chloride (1.14 mmol, 1.1 equiv.). The progress of the reaction was monitored via TLC, 
and once complete, the reaction was quenched with saturated aqueous ammonium chloride 
solution (3 mL). The organic layer was washed twice with saturated ammonium chloride solution, 
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once with brine, dried over sodium sulfate, and concentrated in vacuo. The resulting product was 
dissolved in DMSO and purified by RP-HPLC [Phenomenex Luna C18 column (5 µm, 10 x 250 
mm), water/acetonitrile gradient (70:30 - 10:90 in 30 min) containing 0.1% TFA (v/v); the 
extinction at 240 nm was monitored for detection], to yield the pure phenolic precursor as white 
crystals (33% yield). NMR spectra were acquired on a Varian Inova spectrometer operating at 300 
MHz for 1H and are referenced internally according to residual solvent signals. Data for 1H NMR 
were recorded as follows: chemical shift (δ, ppm), multiplicity (s, singlet; d, doublet; t, triplet; m, 
multiplet; bs, broad singlet), integration, coupling constant (Hz). High-resolution mass spectra 
were obtained from the Vincent Coates Foundation Mass Spectrometry Laboratory at Stanford 
University. 1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.661 (d, 3JH,H = 8.7 Hz, 2H), 7.574 (m, 1H), 
7.075 (m, 2H), 6.987 (d, 3JH,H = 8.7 Hz, 2H), 5.648 (bs, 1H), 3.393 (m, 4H), 3.150 (m, 4H). MS 
(CI) m/z: [M+H]+ calculated for C16H16F2N2O5S2 419.05; found 419.08 (fig. S1).
 
 
DASA-23 was synthesized as a standard to confirm the identity of [11C]DASA-23 using previously 
described methods (12). 1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.685 (d, 3JH,H = 9.4 Hz, 2H), 
7.563 (m, 1H), 7.057 (m, 4H), 3.921 (s, 3H), 3.392 (m, 4H), 3.151 (m, 4H) (fig. S2).   
 
Radiosynthesis 
Synthesis of [11C]DASA-23 (Fig. 2A) was accomplished with a GE TRACERLab FXC Pro module 
by reacting 4-((4-((2,6-difluorophenyl)sulfonyl)piperazin-1-yl)sulfonyl)phenol (2.4 µmol) with 
[11C]methyl triflate in acetonitrile (300 µL) for 3 min at 80 °C, using 5 N NaOH (24 µmol) as base. 
The reaction mixture was diluted with 1 mL water and loaded on a semi-prep HPLC for 
purification (Phenomenex Luna C18 5 µ, 250 x 10 mm, 50% acetonitrile, 50% 0.1 M NH4HCO2 
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with 0.5 % AcOH; 7 mL/min). The fraction corresponding to [11C]DASA-23 (retention time, tR = 
9.5 min) was collected into a round flask preloaded with 20 mL water. The diluted aqueous fraction 
was passed through a pre-conditioned C-18 light Sep-Pak cartridge (Waters). The loaded cartridge 
was washed with sterile water (5 mL). [11C]DASA-23 was eluted from the cartridge using ethanol 
(0.75 mL) and then saline (6.75 mL). The overall synthesis time was 52 min. Analytical HPLC 
(Phenomenex Gemini C18 5 µ, 250 x 4.6 mm, 60% acetonitrile, 40% 0.1 M NH4HCO2 with 0.5 
% AcOH, 1 mL/min) was used for assessment of radiochemical purity and specific activity. 
 
Cell uptake and efflux studies 
U87 and HeLa cells (2  105) were plated into 6-well plates overnight before [11C]DASA-23 
uptake analysis. On the day of the experiment, fresh, pre-warmed DMEM containing 0.925 MBq 
of [11C]DASA-23 was added to individual wells (1 mL/well; 9.25  4.63 pmol). Cells were 
incubated with [11C]DASA-23 at 37 °C and 5% CO2 over a 60 min time course. At the indicated 
time points, plates were placed on ice, washed 3 times with ice-cold phosphate-buffered saline 
(PBS), and lysed in radio-immunoprecipitation assay buffer (Thermo Fisher Scientific Inc.; 500 
µL). 300 µL cell lysates were transferred to counting tubes, and decay-corrected radioactivity was 
determined on a γ counter (Cobra II Auto-Gamma counter; Packard Biosciences Co.). The 
remaining lysate was frozen and used after radioactive decay for protein determination with a 
bicinchoninic acid (BCA) 96-well plate assay (Thermo Fisher Scientific Inc.) and for 
immunoblotting. In addition, 10 µL standards from the 0.925 MBq/mL solution added to cells 
were counted to quantitate percentage radiotracer uptake. For efflux studies, cells were incubated 
with radiotracer for 60 min and washed 3 times with room temperature (RT) Hank’s Buffered Salt 
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Solution (HBSS) before subsequent incubation at 37 °C in fresh, radiotracer-free, DMEM. At the 
specified times, samples were processed as described above. 
 
PKM2 siRNA 
PKM2 knockdown in HeLa cells was performed over a time course of 72 hours after transfection. 
Cells were seeded in 6-well plates in antibiotic-free DMEM at 1.5 × 106 cells/well 24 hours before 
siRNA transfection with DharmaFECT1 (Thermo Scientific), according to the manufacturer’s 
instructions. Specific siRNA targeting only PKM2 were custom made by Thermo Scientific using 
the following sequences: CCAUAAUCGUCCUCACCAAUU (sense), 
UUGGUGAGGACGAUUAUGGUU (antisense) (37).  Scrambled siRNA (siCtrl; Cell Signaling 
Technology) was used as a control. siRNA were added at a final concentration of 25 nM. 
[11C]DASA-23 uptake (0.925 MBq/mL) was measured after 30 min in cells transfected with siCtrl 
and siPKM2 at 24, 48, and 72 hours after transfection, after being processed as described in ‘Cell 
uptake and efflux studies’. Untreated cells were used as a further control, measured 24 hours after 
addition of fresh DMEM and 96 hours after seeding.  
 
Western blotting 
Monoclonal rabbit antibodies to PKM1 and PKM2 (1:1000 dilution, Cell Signaling Technology) 
were used in a standard western blotting protocol. A rabbit anti-actin antibody (Sigma-Aldrich Co. 
Ltd; 1:2000) was used as a loading control. Blots were scanned and signal was quantified with 
ImageJ (National Institutes of Health). 
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In vivo tumor models 
All experimental procedures involving animals were approved by Stanford University Institutional 
Animal Care and Use Committee. For s.c. tumor models, U87 tumor cells (5 × 106 cells; 100 µL 
PBS) were injected subcutaneously on the back of female BALB/c nude mice (aged 6 – 8 weeks; 
Charles River Laboratories) and grown to ~150 mm3. Tumor dimensions were measured 
periodically using a caliper (by the same researcher), with tumor volumes calculated by the 
equation: volume = (π / 6) × a × b × c, where a, b, and c represent three orthogonal axes of the 
tumor. For orthotopic brain tumor models, either 2 × 105 U87 or 4 × 105 GBM39 cells were 
implanted in the right hemisphere, 0.5 mm anterior and 2 mm lateral to the lambda, in the brains 
of 6 – 8 week-old nude mice held in place with a stereotaxic unit (Stoelting). The cells, suspended 
in 4 µL PBS, were injected at a depth of 3 mm over 5 min with an AS blunt-ended Hamilton 
syringe, which was subsequently held in place for a further 5 min. Animals were anesthetized with 
an i.p. injection of 150 mg/kg ketamine, 15 mg/kg xylazine. U87 tumor-bearing mice were 
subsequently imaged by MRI and PET 32-35 days after intracranial injection, and GBM39 tumor-
bearing mice were imaged between 44-50 days after implantation. For blocking studies, mice were 
imaged with [11C]DASA-23 at baseline and then 24 hours later with a second tail-vein injection of 
[11C]DASA-23, 1 hour after i.p. injection of TEPP-46 [50 mg/kg in 40% w/v (2-hydroxypropyl)-
-cyclodextrin in water; ~3 µmol; Cayman Chemical]. 
 
Imaging studies 
MRI was performed at the Stanford Clark Center Small Animal Imaging Facility in an actively-
shielded Discovery MR901 General Electric 7T horizontal bore scanner (GE Healthcare) including 
Integrated Electronics Company (IECO) gradient drivers, an Agilent 120 mm inner 
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diameter shielded gradient insert (600 mT/m, 1000 T/m/s), EXCITE2 electronics, the supporting 
LX11 platform, and a 3 cm inner diameter Millipede quadrature transmit/receive volume RF coil. 
Animals were anesthetized with 2% isoflurane in oxygen, and physiological monitoring included 
respiration and temperature feedback for maintaining surface body temperature by warm airflow 
over the animal. A fast spoiled gradient echo (FSPGR) sequence (TR = 9.7 ms; TE = 2.1 ms; flip 
angle = 5°; NEX = 20; FOV = 2 cm; image matrix = 160 × 160; slice thickness = 1 mm) was used 
to acquire 3 sets of 12, 12, and 8 orthogonal T1-weighted images in the axial, sagittal, and coronal 
planes through the mass, respectively. PET-MR registration was performed in IRW (Siemens) 
using the CT image for alignment of the skull.  
 
PET imaging scans were carried out on a docked Siemens Inveon PET/CT scanner (matrix size, 
128 × 128 × 159; CT attenuation-corrected; non-scatter corrected), after a bolus i.v. injection of 
~18.5 MBq of [11C]DASA-23 into tumor-bearing mice (185  92.5 pmol). Dynamic scans were 
acquired in list mode format over 60 min. The acquired data were then sorted into 0.5-mm 
sinogram bins and 19 time frames for image reconstruction (4 × 15 s, 4 × 60 s, and 11 × 300 s), 
which was done by iterative reconstruction with the following parameters: 3D ordered-subsets 
expectation maximization (3D-OSEM) followed by fast maximum a posteriori (fastMAP); MAP 
OSEM iterations, 2; MAP subsets, 16; MAP iterations, 18. The count densities were averaged for 
all volumes of interest at each time point to obtain a time versus radioactivity curve (TAC). Tumor 
and tissue TACs were normalized to injected dose, measured by a CRC-15 PET dose calibrator 
(Capintec, Inc.), and expressed as percentage injected dose per gram of tissue (%ID/g), assuming 
1 g/mL. The normalized uptake of radiotracer at 30 min (%ID/g30) was also used for comparison. 
Siemens Inveon Research Workplace software (v.4.0) was used for visualization of radiotracer 
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uptake in the tumor, to define the three-dimensional (3D) volumes of interest (VOI) and for 3D 
visualisation to create volume rendering technique (VRT) images.  
 
Ex vivo biodistribution 
After the PET imaging studies, 60 min after radiotracer administration, mice were sacrificed by 
exsanguination via cardiac puncture and tissues were harvested. Tissue radioactivity for all organs 
was subsequently determined on a gamma counter (decay-corrected; Cobra II Auto-Gamma 
counter, Packard Biosciences Co.). Ten-microliter standards from the stock activity were also 
counted for data normalization. Data were expressed as percent injected dose per gram of tissue 
(%ID/g). 
 
Ex vivo autoradiography 
Autoradiography was performed as in (38). In brief, coronal brain sections of U87 and GBM39 
tumor-bearing mice were obtained 20 min after i.v. injection of 26 MBq [11C]DASA-23. 
Anesthetized mice were perfused with saline (10 mL) to remove intravascular [11C]DASA-23, and 
after cervical dislocation, the brain was removed and embedded in optimal cutting temperature 
(OCT) compound (Tissue-Tek) before being frozen on dry ice. Subsequently, 10 μm thick coronal 
brain sections were cut with a cryostat microtome HM500 (Microm). The sections were mounted 
on microscope slides (Fisherbrand Superfrost Plus microscope slides), air-dried for a minimum of 
5 min, and then exposed to MultiSensitive storage phosphor screens (Perkin-Elmer) for 3 hours at 
-20 °C. The image plates were analyzed with a Typhoon 9410 variable mode imager (Amersham 
Biosciences), and image data were visualized and processed by Image J. 
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Plasma stability 
[11C]DASA-23 stability in mouse plasma was assessed ex vivo according to previously described 
methodology (38). Samples were incubated for 10, 30, and 60 min and compared to a standard 
from the respective injected radiotracer formulation. 
 
Histopathology 
After imaging, anesthetized mice bearing orthotopically-implanted U87 tumors were 
transcardially perfused with 0.9% saline, followed by the removal of the brain. Formalin-fixed 
brains (10% v/v) were embedded in paraffin, coronally sectioned into 5 µm-thick slices and 
mounted on microscope slides according to standard procedures (Histo-Tec laboratory). Sections 
were taken at regular intervals across the entire brain. Every sixth section was stained with 
hematoxylin and eosin (H&E; Histo-Tec laboratory). Immunohistochemistry against PKM1 and 
PKM2 was performed on paraffin-embedded sections with rabbit monoclonal antibodies reactive 
to both mouse and human isozymes (Cell Signaling Technology; 1:100) using standard techniques 
and according to the manufacturer’s instructions (Cell Signaling Technology). Before staining, 
antigen retrieval was performed in 10 mM sodium citrate buffer at 90 °C for 10 min. For detection, 
VECTASTAIN Elite ABC and Vector NovaRED (Vector Laboratories) were used per 
manufacturer’s recommendations. Histopathological staining (H&E and PKM2) of fresh-frozen 
sections taken for autoradiography was processed using standard techniques and according to the 
manufacturer’s instructions (Cell Signaling Technology). 
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Statistical analysis 
Data were expressed as mean ± SD. Statistical significance was determined using a two-tailed 
Student’s t test. Paired t tests were used for longitudinal studies (Fig. 6E), with unpaired t tests 
used to derive significance for all other analyses. For the analysis of [11C]DASA-23 uptake in 
multiple tissues, significance was determined by ANOVA, followed by Tukey’s honest significant 
difference test. Correlation analysis using Spearman’s rank correlation, linear regression, 
statistical significance, and 95% confidence levels were determined using Prism software for Mac 
OSX (v.6.0e; GraphPad Software). Differences between groups were considered significant if P ≤ 
0.05. 
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Supplementary Materials 
Fig. S1. Precursor identification by 1H-NMR spectrum and mass spectrometry. 
Fig. S2. Confirmation of DASA-23 identity by 1H-NMR spectrum. 
Fig. S3. Analytical HPLC chromatogram of purified [11C]DASA-23. 
Fig. S4. Pyruvate kinase protein expression in HeLa cells 72h post transfection with siPKM2 or 
siCtrl. 
Fig. S5. Initial delivery of [11C]DASA-23 to orthotopic U87 tumors and corresponding 
contralateral normal brain. 
Fig. S6. Time course images of [11C]DASA-23 uptake in the brain of an orthotopic U87 tumor-
bearing mouse.   
Fig. S7. Cytosolic immunostaining of tumor-specific PKM2 at the tumor margin.   
Fig. S8. Ex vivo histopathological and autoradiographic analysis of orthotopic GBM tumors. 
Movie S1. Overlaid PET/CT 3D volume rendering technique movie from the head of a mouse 
containing an orthotopic U87 xenograft. 
Movie S2. Overlaid PET/CT 3D volume rendering technique movie from the head of a non tumor-
bearing mouse. 
Movie S3. Overlaid PET/CT 3D volume rendering technique movie from the head of a mouse 
containing an orthotopic GBM39 PDX. 
Movie S4. Overlaid PET/CT 3D volume rendering technique movie from the head of the same 
orthotopic GBM39-tumoured mouse as supplemental movie S3, 1h post blocking with TEPP-46 
(50 mg/kg). 
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Figures 
 
Fig. 1. Schematic illustrating the control of normal and tumor cell glycolysis by pyruvate 
kinase M2. Pyruvate kinase catalyzes the final step of glycolysis, resulting in net ATP synthesis 
through the dephosphorylation of phosphoenolpyruvate. The pyruvate kinase M2 (PKM2) 
isozyme predominates in proliferating non-tumor and tumor cells. Two quaternary PKM2 
conformations exist as homo-dimeric or –tetrameric forms (shown above as two orange spheres 
and four orange spheres, respectively). Dimeric PKM2 has reduced affinity for 
phosphoenolpyruvate in comparison to the tetramer, with tumor PKM2 mainly present in the 
dimeric form. The reduced conversion of phosphoenolpyruvate to pyruvate results in a buildup of 
glycolytic precursors that can subsequently be used by alternative pathways for the biosynthesis 
of cellular macromolecules. Conversely, PKM2 is mostly present in the tetrameric form in non-
tumor cells. 
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Fig. 2. Radiosynthesis, tumor cell uptake, retention, and washout of [11C]DASA-23. (A). 
Synthesis of the precursor 4-((4-((2,6-difluorophenyl)sulfonyl)piperazin-1-yl)sulfonyl)phenol, 
and the 11C-labeled compound [11C]DASA-23 (1-((2,6-difluorophenyl)sulfon-yl)-4-((4-(methoxy-
11C)phenyl)sulfonyl)piperazine). Reagents and conditions: (i) dichloromethane, triethylamine, 0 
°C, 1 h; (ii) dichloromethane, trifluoroacetic acid, 0 °C, 1 h; (iii) dichloromethane, triethylamine, 
0 °C, 1 h; (iv) acetonitrile, [11C]methyl triflate, NaOH, 80 °C, 3 min. The radioisotope is labeled 
in red. Cell uptake and washout of [11C]DASA-23 was assessed in human HeLa cervical 
adenocarcinoma (B) and U87 glioma cells (C). Data shown as mean ± SD (n = 3). 
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Fig. 3. Specificity of [11C]DASA-23 for detecting PKM2 expression in cells. (A) Time course 
of PKM2 knockdown by siRNA in HeLa cells in comparison to scrambled siRNA and untreated 
control cells. Representative western blot from whole cell lysate is shown, with actin used as a 
loading control. (B) [11C]DASA-23 cell uptake after perturbation of PKM2 expression. (C) 
Correlation between PKM2 protein expression and [11C]DASA-23 uptake after PKM2 
knockdown. 95% confidence levels are represented as dashed lines. Data shown as mean ± SD (n 
= 3). *, P = 0.011; ***, P = 0.0006, P = 0.0001, and P = 0.0045 for 24 h, 48 h, and 72 h siRNA 
treatment, and for the correlation between PKM2 protein and [11C]DASA-23 uptake, respectively. 
Abbreviations: UT, untreated; Ctrl, control. 
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Fig. 4. PET/CT imaging, ex vivo biodistribution, and stability of [11C]DASA-23 in mice 
bearing subcutaneous U87 glioblastoma xenografts. (A) Representative 30-60 min sagittal and 
axial fused PET/CT images. Nude mice received ~18.5 MBq of [11C]DASA-23 via tail vein 
injection, with PET/CT images acquired 30-60 min after injection. Arrowheads indicate the tumor, 
identified from the CT image. (B) Ex vivo biodistribution at 60 min after injection. Data shown as 
mean ± SD (n = 6 animals). *, P < 0.05; ***, P < 0.001. (C) Ex vivo mouse serum stability of 
[11C]DASA-23. [11C]DASA-23 was incubated in mouse serum for the indicated amounts of time 
at 37 °C and compared to a [11C]DASA-23 standard. Peak 1, [11C]DASA-23; Peak 2, unknown 
metabolite. (D) Temporal urinary and (E) hepatobiliary excretion of [11C]DASA-23 by dynamic 
PET. (F) The tumor TAC representing average counts from a dynamic 60-minute scan for U87 
s.c. tumors compared to [11C]DASA-23 uptake profiles for the muscle and normal brain. Data 
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shown as mean ± SD (n = 3 animals). Abbreviations: L, liver; S, salivary gland; SI, small intestine; 
K, kidney; B, bladder; Br, brain; LI, large intestine. 
 
 
Fig. 5. Non-invasive imaging of mice bearing orthotopic U87 human gliomas. (A) 
Representative fused [11C]DASA-23-PET/CT (10 – 30 min summed activity) 3D volume 
rendering technique (VRT) image of the head of a mouse containing an orthotopically-grown U87 
tumor. Gray scale is CT image and color scale is PET image. The long white arrow indicates the 
tumor. [11C]DASA-23 accumulation in the harderian glands is indicated by white arrow heads. (B) 
Orthotopic U87 tumor and corresponding contralateral normal brain TAC taken from dynamic 
[11C]DASA-23-PET/CT images. Data shown as mean ± SD (n = 6 animals). **, P < 0.01. (C) 
Representative contrast-enhanced T1-weighted MR coronal and horizontal images of 
orthotopically-implanted U87 gliomas. (D) Corresponding merged [11C]DASA-23-PET/MR 
images (10 – 30 min summed [11C]DASA-23 activity). Arrows and dashed circles indicate regions 
of contrast enhancement and radiotracer uptake, corresponding to the tumor. (E) Histopathological 
analysis of orthotopic U87 human gliomas. Whole brain sections were stained with H&E, PKM2, 
or PKM1 (scale bar = 5 mm). Higher magnification views of the boxed areas in the tumor periphery 
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are also displayed (10×; scale bar = 250 µm). Arrows indicate U87 tumor cells infiltrating away 
from the margins of the primary tumor. T1W-MRI, T1-weighted nuclear magnetic resonance 
imaging. 
 
Fig. 6. Assessment of TEPP-46 binding efficacy with [11C]DASA-23 in orthotopic GBM39 
PDX tumors. (A) Bioluminescence imaging of an orthotopically-implanted GBM39 tumor 50 
days after injection. (B) [11C]DASA-23 PET/CT (10 – 30 min summed activity) images of the 
head of a GBM39 tumor-bearing mouse at baseline, reimaged the following day 1 hour after TEPP-
46 injection (50 mg/kg i.p.). Arrows indicate the location of the tumor. (C) 3D VRT images of the 
same animal. Arrows indicate the location of the tumor. H, harderian glands; S, salivary glands. 
(D) Merged [11C]DASA-23-PET/MR images (10 – 30 min summed [11C]DASA-23 activity) at 
baseline and after TEPP-46 injection. Arrows indicate the location of the tumor. (E) Semi-
quantitative uptake values in GBM39 tumors before and after TEPP-46 blocking, taken 30 min 
after [11C]DASA-23 injection. Data shown as mean ± SD (n = 7 animals).  BLI, 
bioluminescence imaging; T1W-MRI, T1-weighted nuclear magnetic resonance imaging; NS, not 
significant; VRT, volume rendering technique. ***, P < 0.001.  
